Food and Drug Administration

Arthritis Advisory Committee

March 4, 2003

Briefing Information

Table of Contents (PDF)

Update on the TNF-a Blocking Agents (HTM) (PDF) (Word)

Clinical Review, Adalimumab - for use in the Treatment of Rheumatoid Arthritis, Dr. Scheldon Kress, MD (PDF) (Word)

Reveiw of Etanercept in Congestive Heart Failure (HTM) (PDF) (Word)

Briefing Information Regarding Infliximab (Remicade®) and Congestive Heart Failure (HTM) (PDF) (Word)

Errata (PDF)


The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Briefing Information Regarding Humira™ (Adalimumab), Abbott Laboratories (HTM) (PDF) (Word)

Humira™ (Adalimumab), Prescribing, Abbott Laboratories (PDF)

Briefing Information Regarding Enbrel® (Etanercept), Amgen (HTM) (PDF) (Word)

Errata (HTM) (PDF) (Word)

Briefing Information Regarding Remicade® (Infliximab), Centocor, Inc. (PDF)

Errata (PDF)